A molecular on/off switch for CRISPR – Phys.Org
Phys.Org |
A molecular on/off switch for CRISPR
Phys.Org This image shows how the CRISPR surveillance complex is disabled by two copies of anti-CRISPR protein AcrF1 (red) and one AcrF2 (light green). These anti-CRISPRs block access to the CRISPR RNA (green tube) preventing the surveillance …more. |
Nature.com |
Japanese man is first to receive ‘reprogrammed’ stem cells from another person
Nature.com The surgery is expected to set the path for more applications of iPS cell technology, which offers the versatility of embryonic stem cells without the latter’s ethical taint. Banks of iPS cells from diverse donors could make stem cell transplants more … |
EurekAlert (press release) |
A molecular on/off switch for CRISPR
EurekAlert (press release) The research team, co-led by biologist Gabriel C. Lander of The Scripps Research Institute (TSRI), discovered that anti-CRISPR proteins work by locking down CRISPR’s ability to identify and attack the viral genome. One anti-CRISPR protein even “mimics” … |
EurekAlert (press release) |
A molecular on/off switch for CRISPR
EurekAlert (press release) The research team, co-led by biologist Gabriel C. Lander of The Scripps Research Institute (TSRI), discovered that anti-CRISPR proteins work by locking down CRISPR’s ability to identify and attack the viral genome. One anti-CRISPR protein even “mimics” … |
Phys.Org |
Discovery of a new regulatory protein provides new tool for stem cell engineering
Phys.Org An artistic rendering showing that the interaction between SMARCAD1 and H3R26Cit modified histones can be skillfully manipulated — as if in a game of pinball — to regulate the switch of embryonic stem cells from the naïve to the primed pluripotent state. |
Immuno-Oncology News |
Chronix Blood Test Can Predict Cancer Patients’ Response to Immunotherapy, Study Shows
Immuno-Oncology News Chronix’s test predicted treatment response and disease control or progression with 83 percent accuracy. It also predicted disease progression after one cycle of immunotherapy with 92 percent accuracy, and after two cycles with 100 percent accuracy. |